International journal of laboratory hematology · 2026
Splenic B-Cell Lymphoma/Leukemia With TCL1 Gene Rearrangement.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xin, Tang Guilin, Hu Zhihong, Medeiros L Jeffrey, Hu Shimin
Аннотация
BACKGROUND: Splenic B-cell lymphoma/leukemia includes a group of indolent small B-cell lymphomas/leukemias that share overlapping morphological and immunophenotypic features, making accurate diagnosis challenging. Specific gene rearrangements have not been commonly associated with splenic B-cell lymphomas/leukemias, and the TCL1 gene rearrangement-characteristic of T-cell prolymphocytic leukemia-has not been previously reported in B-cell lymphomas/leukemias. Here, we report two unique cases of splenic B-cell lymphoma/leukemia harboring an IGH::TCL1 rearrangement.
CASE PRESENTATION: Patient #1 was a 74-year-old man with a 25-year history of low-grade B-cell leukemia involving the peripheral blood, spleen, and bone marrow. Patent #2 was a 54-year-old woman who recently presented with lymphocytosis and low-level bone marrow involvement. Both patients were asymptomatic and incidentally found to have lymphocytosis. The neoplastic cells in both cases displayed polar villous cytoplasmic projections, were of B-cell lineage, and were negative for CD5 and CD10. Notably, an IGH::TCL1 fusion was identified in both cases.
CONCLUSIONS: The identification of IGH::TCL1 fusion in these two cases of splenic B-cell lymphoma/leukemia suggests that TCL1 gene rearrangements can occur in B-cell lymphoma/leukemia and should not be considered exclusive to T-cell prolymphocytic leukemia. Accurate diagnosis of splenic B-cell lymphoma/leukemia with TCL1 rearrangement requires evaluation of morphologic and immunophenotypic features and genetic assessment of TCL1.
CASE PRESENTATION: Patient #1 was a 74-year-old man with a 25-year history of low-grade B-cell leukemia involving the peripheral blood, spleen, and bone marrow. Patent #2 was a 54-year-old woman who recently presented with lymphocytosis and low-level bone marrow involvement. Both patients were asymptomatic and incidentally found to have lymphocytosis. The neoplastic cells in both cases displayed polar villous cytoplasmic projections, were of B-cell lineage, and were negative for CD5 and CD10. Notably, an IGH::TCL1 fusion was identified in both cases.
CONCLUSIONS: The identification of IGH::TCL1 fusion in these two cases of splenic B-cell lymphoma/leukemia suggests that TCL1 gene rearrangements can occur in B-cell lymphoma/leukemia and should not be considered exclusive to T-cell prolymphocytic leukemia. Accurate diagnosis of splenic B-cell lymphoma/leukemia with TCL1 rearrangement requires evaluation of morphologic and immunophenotypic features and genetic assessment of TCL1.